| __timestamp | ADMA Biologics, Inc. | Amphastar Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 40373000 |
| Thursday, January 1, 2015 | 6745968 | 46974000 |
| Friday, January 1, 2016 | 8494742 | 47298000 |
| Sunday, January 1, 2017 | 18092835 | 50918000 |
| Monday, January 1, 2018 | 22502922 | 58044000 |
| Tuesday, January 1, 2019 | 25910757 | 63109000 |
| Wednesday, January 1, 2020 | 35050817 | 65157000 |
| Friday, January 1, 2021 | 42896889 | 68920000 |
| Saturday, January 1, 2022 | 52458024 | 66592000 |
| Sunday, January 1, 2023 | 59020000 | 80393000 |
Unlocking the unknown
In the competitive landscape of biopharmaceuticals, effective cost management is crucial. Over the past decade, ADMA Biologics, Inc. and Amphastar Pharmaceuticals, Inc. have demonstrated distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, ADMA Biologics saw a staggering 1,124% increase in SG&A expenses, reflecting its aggressive growth strategy. Meanwhile, Amphastar Pharmaceuticals maintained a more stable growth, with a 99% rise over the same period. By 2023, Amphastar's SG&A expenses were approximately 36% higher than ADMA's, highlighting its larger operational scale. This data underscores the importance of strategic financial planning in sustaining competitive advantage in the biopharma sector. As these companies continue to evolve, monitoring their cost management strategies will provide valuable insights into their future market positioning.
Selling, General, and Administrative Costs: argenx SE vs Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amphastar Pharmaceuticals, Inc.
Summit Therapeutics Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Amphastar Pharmaceuticals, Inc.
Alpine Immune Sciences, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for ADMA Biologics, Inc. and Rhythm Pharmaceuticals, Inc.
ADMA Biologics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Analyzing R&D Budgets: ADMA Biologics, Inc. vs Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.